What was the primary driver of McKesson's revenue growth in this quarter?

McKesson's revenue growth of 10% to $21.1 billion was primarily driven by its Pharmaceutical Solutions segment, which represents the largest portion of its consolidated revenues. Growth in this segment was attributed to increased pharmaceutical direct distribution and services, as well as Canadian distribution and services.

Why did net income not grow despite the increase in revenues?

Net income remained flat at $171 million due to a significant Securities Litigation charge of $35 million (after-tax) recorded in the current quarter. This charge offset the gains in operating profit from the company's core business segments and the overall revenue growth.

What are the key acquisitions McKesson is pursuing?

McKesson has entered into agreements to acquire D&K Healthcare Resources, Inc. for approximately $207 million, which will expand its pharmaceutical distribution to independent pharmacies. Additionally, the company plans to acquire Medcon, Ltd. for approximately $105 million, a move that will enhance its Provider Technologies segment with web-based cardiac image and information management services.

How is McKesson managing its significant legal liabilities, specifically the Securities Litigation?

McKesson has recorded a substantial accrual of $1.221 billion as of June 30, 2005, for its Securities Litigation. While the company believes this accrual is adequate, it acknowledges the uncertainties inherent in litigation, and the ultimate costs could exceed or be below the current reserve, potentially impacting financial results.

MCK 10-Q Quarterly Report Q1 FY2006 — Revenue, Net Income, EPS

Summary

McKesson Corporation's (MCK) 10-Q filing for the quarter ending June 30, 2005, shows a solid increase in revenues, growing 10% year-over-year to $21.1 billion. This growth was primarily driven by the Pharmaceutical Solutions segment. Despite this top-line growth, net income remained flat at $171 million, with diluted Earnings Per Share (EPS) at $0.55 for both periods. This flat performance in profitability is largely attributable to a significant Securities Litigation charge of $35 million (after-tax) recorded in the current quarter, which offset gains in operating profit from core segments. Investors should note the company's strategic acquisitions, including agreements to acquire D&K Healthcare Resources and Medcon, Ltd., indicating a focus on expanding its market reach and service offerings. The company also continues to manage its legal liabilities, with a substantial accrual for Securities Litigation, which it believes is adequate but carries inherent uncertainties.

Key Highlights

1Revenues increased by 10% to $21.1 billion, driven by strong performance in the Pharmaceutical Solutions segment.
2Net income remained stable at $171 million, with diluted EPS of $0.55, impacted by a $35 million after-tax Securities Litigation charge.
3The company announced agreements to acquire D&K Healthcare Resources (pharmaceutical distribution) and Medcon, Ltd. (cardiac image management).
4Operating profit from the Provider Technologies segment saw significant growth (121%), indicating successful expansion in this area.
5McKesson maintained a strong liquidity position, with cash and cash equivalents of $2.4 billion and an undrawn credit facility.
6A substantial accrual of $1.221 billion exists for Securities Litigation, with ongoing legal developments and potential for future impacts.
7The company repurchased approximately 1.6 million shares for $66 million during the quarter as part of its ongoing share repurchase program.

MCKESSON CORP Quarterly Report for Q1 Ended Jun 30, 2005

Summary

Key Highlights

Frequently Asked Questions